Two teams of researchers, one working in the U.S., the other in Italy, have come up with new ways to avert cytokine release syndrome (CRS) in leukemia patients who undergo CAR T-cell therapies. In the first, the researchers working at the Sloan Kettering Cancer Center in New York developed a mouse model to replicate the conditions under which CRS develops. […]

Continue reading »